Opendata, web and dolomites

Pituitary enhancers SIGNED

Identification and functional validation of novel enhancer sequences involved in pituitary gland development and pathology

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Pituitary enhancers project word cloud

Explore the words cloud of the Pituitary enhancers project. It provides you a very rough idea of what is the project "Pituitary enhancers" about.

hypothesis    luciferase    vitro    indicator    reporter    seq    conducting    regulation    regulatory    de    gpr10    variations    expression    domain    sequencing    transcriptional    fundamental    normal    histone    sanger    linked    mutations    duplications    mechanisms    cnv    disorders    lag    remarkably    putative    chip    creation    health    assays    patients    tumors    located    enhancers    physiological    functionally    abnormal    gpr101    molecular    chromatin    cells    local    marks    duplicated    place    pursuing    structure    verified    human    causing    structural    gene    pituitary    transcription    clinical    elucidate    validate    performed    overexpression    perform    showing    methylation    functional    enhancer    children    genome    preliminary    pathological    underlying    accessibility    characterization    tumoral    promoter    novo    profile    there    silico    4c    pathologies    sequences    regulates    acrogigantism    region    screen    interactions    tested    central    disrupt    gap   

Project "Pituitary enhancers" data sheet

The following table provides information about the project.

Coordinator
HUMANITAS MIRASOLE SPA 

Organization address
address: VIA MANZONI 56
city: ROZZANO (MI)
postcode: 20100
website: www.humanitas.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 183˙473 €
 EC max contribution 183˙473 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2020
 Duration (year-month-day) from 2020-03-16   to  2022-03-15

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HUMANITAS MIRASOLE SPA IT (ROZZANO (MI)) coordinator 183˙473.00

Map

 Project objective

There is a fundamental gap in understanding how the GPR101 gene regulates human growth in physiological and pathological conditions. Children’s growth is remarkably clinical relevant and is an important indicator of their health and general well-being. The specific objective of this proposal is to identify the molecular mechanisms underlying GPR101 overexpression in the pituitary tumors of children with GPR101 duplications causing X-linked acrogigantism (X-LAG). My central hypothesis is that GPR101 duplications disrupt the structure of the local chromatin, leading to the creation of a new chromatin domain where de novo enhancer-promoter interactions take place, causing abnormal GPR101 expression. This hypothesis will be tested by pursuing three specific aims: 1. Elucidate the transcriptional regulation of GPR101 in normal and pathological conditions 2. Identify and functionally characterize novel pituitary-specific enhancer sequences 3. Investigate these regulatory sequences in patients with different pituitary pathologies. To achieve aim 1) I will perform an in vitro functional characterization of GPR101 promoter: promoter activity will be studied by luciferase-based reporter assays, by conducting a methylation analysis, and by determining its accessibility to transcription factors. To achieve aim 2) I will validate my preliminary results showing the formation of a novel chromatin domain by 4C-Seq. Four putative enhancer sequences located within the duplicated GPR10 region and identified in silico will be functionally evaluated in vitro to establish their impact on transcriptional activity. To identify novel pituitary-specific enhancers, a whole-genome profile of enhancer-specific histone marks will be performed in normal and tumoral pituitary cells by ChIP-Seq. To achieve aim 3) I will screen patients with different pituitary disorders for mutations (Sanger sequencing) and structural variations (CNV assays) in the functionally-verified enhancers.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PITUITARY ENHANCERS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PITUITARY ENHANCERS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

STIMOS (2019)

Stimulation of Multiple Organoids Simultaneously

Read More  

VINCI (2020)

The Value of Information and Choice to Improve Control.

Read More  

BirthControlEnvirons (2019)

Contraception meets the environment: everyday contraceptive practices, politics, and futures in a toxic age

Read More